1. Home
  2. PNTG vs CGEN Comparison

PNTG vs CGEN Comparison

Compare PNTG & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Pennant Group Inc.

PNTG

The Pennant Group Inc.

N/A

Current Price

$34.20

Market Cap

1.0B

Sector

Health Care

ML Signal

N/A

Logo Compugen Ltd.

CGEN

Compugen Ltd.

N/A

Current Price

$2.15

Market Cap

148.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PNTG
CGEN
Founded
2019
1993
Country
United States
Israel
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
148.7M
IPO Year
2019
2001

Fundamental Metrics

Financial Performance
Metric
PNTG
CGEN
Price
$34.20
$2.15
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
1
Target Price
$36.83
$4.00
AVG Volume (30 Days)
276.3K
295.6K
Earning Date
05-27-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
20.00
N/A
EPS
0.84
N/A
Revenue
$947,705,000.00
N/A
Revenue This Year
$24.09
N/A
Revenue Next Year
$7.99
$58.57
P/E Ratio
$40.04
N/A
Revenue Growth
36.31
N/A
52 Week Low
$21.74
$1.13
52 Week High
$35.00
$2.38

Technical Indicators

Market Signals
Indicator
PNTG
CGEN
Relative Strength Index (RSI) 62.08 61.33
Support Level $27.34 $1.45
Resistance Level $35.00 $2.38
Average True Range (ATR) 1.58 0.14
MACD 0.08 0.04
Stochastic Oscillator 88.25 73.08

Price Performance

Historical Comparison
PNTG
CGEN

About PNTG The Pennant Group Inc.

Pennant Group Inc is engaged in providing healthcare services to patients of all ages, including the growing senior population, in the United States. It operates in multiple lines of business including home health, hospice, and senior living which includes the company's assisted living, independent living, and memory care communities across Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The company generates majority of its revenue from home health and hospice services segment, which includes its home health, hospice and home care businesses.

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

Share on Social Networks: